在免疫疗法时代,针对骨的药物仍然有用吗? 在SAKK 80/19 BTA试点研究SAKK 80/19 BTA试点研究
Michael Mark1,2, Alfonso Rojas Mora3, Thomas Winder4
1Division of Oncology/Hematology, Cantonal Hospital Graubuenden, Chur, Switzerland.
Bone reports
|August 14, 2024
概括
针对骨的药物 (BTAs) 在接受免疫治疗的患者中没有显著减少症状骨事件 (SSEs). 需要进一步的研究来评估BTA在这个人群中的使用情况.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 骨转移管理 骨转移管理
背景情况:
- 固体瘤造成的骨转移往往需要针对骨的药物 (BTAs) 来预防症状性骨事件 (SSEs).
- 在接受免疫疗法 (IO) 的患者中,BTAs的作用尚不清楚.
研究的目的:
- 研究BTA在免疫治疗患者中预防SSE的疗效.
- 为了比较接受免疫治疗的患者与或没有额外的BTA治疗的结果.
主要方法:
- 对接受免疫疗法治疗的骨转移患者进行了回顾性分析.
- 患者根据他们是否接受了额外的BTA (登索苏马布或龙酸) 进行分类.
- 主要终点是第一次SSE的时间,用于分析的Kaplan-Meier估计.
主要成果:
- 在接受BTA和未接受BTA的患者之间,在第一次SSE或骨疼痛的时间中没有发现显著差异.
- 虽然接受BTA的患者在6个月后显示出减少SSE的趋势,但这并没有达到统计学意义.
- 总生存率 (OS) 在各组之间有显著差异,有利于那些接受BTA治疗的人.
结论:
- 在接受免疫治疗的患者中,BTAs在减少SSEs或骨疼痛方面没有显著的益处.
- 在这种患者群体中使用BTA需要进一步调查.
- 观察到的OS差异表明BTA的潜在好处需要进一步研究.
相关概念视频
01:27Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K